83 related articles for article (PubMed ID: 17327515)
1. Heart groups issue advisories for reducing drug-eluting stent risks.
Mitka M
JAMA; 2007 Feb; 297(8):797-8. PubMed ID: 17327515
[No Abstract] [Full Text] [Related]
2. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
Price MJ; Endemann S; Gollapudi RR; Valencia R; Stinis CT; Levisay JP; Ernst A; Sawhney NS; Schatz RA; Teirstein PS
Eur Heart J; 2008 Apr; 29(8):992-1000. PubMed ID: 18263931
[TBL] [Abstract][Full Text] [Related]
3. Drug-eluting stent thrombosis: an oversensationalized but unresolved problem?
Latib A; Chieffo A; Colombo A
Monaldi Arch Chest Dis; 2007 Mar; 68(1):1-5. PubMed ID: 17564287
[No Abstract] [Full Text] [Related]
4. Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
Jang SW; Kim DB; Kwon BJ; Shin D; Her SH; Park CS; Park HJ; Park MW; Cho EJ; Rho TH; Kim JH
Int J Cardiol; 2010 Apr; 140(1):e8-11. PubMed ID: 19117624
[TBL] [Abstract][Full Text] [Related]
5. Stent thrombosis in the era of drug eluting stents.
Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
[TBL] [Abstract][Full Text] [Related]
6. Resistance to what, does it matter? How do we study it?
Holmes DR
Eur Heart J; 2008 Apr; 29(8):957-8. PubMed ID: 18346961
[No Abstract] [Full Text] [Related]
7. A threshold of platelet reactivity for ischaemic events?
Bonello L; Camoin-Jau L; Dignat-George F; Paganelli F
Eur Heart J; 2008 Sep; 29(17):2185-6; author reply 2187. PubMed ID: 18617480
[No Abstract] [Full Text] [Related]
8. [The bioresorbable coronary stent: a revolution].
Koegler F; De Benedetti E
Rev Med Suisse; 2013 Apr; 9(381):775-8. PubMed ID: 23659156
[TBL] [Abstract][Full Text] [Related]
9. [Developments in percutaneous coronary intervention and coronary stents].
Simsek C; Daemen J; Zijlstra F
Ned Tijdschr Tandheelkd; 2014; 121(7-8):375-9. PubMed ID: 25174186
[TBL] [Abstract][Full Text] [Related]
10. Is conventional antiplatelet therapy for the prevention of coronary stent thrombosis always safe? A case report of a patient with polycythemia vera.
Zavalloni D; Marsico F; Milone F; Presbitero P
Ital Heart J; 2004 Feb; 5(2):163-6. PubMed ID: 15086149
[TBL] [Abstract][Full Text] [Related]
11. [Drug-eluting stents can increase the risk of late stent thrombosis].
Skyttberg N; Linder R; Carlsson J
Lakartidningen; 2006 Sep 27-Oct 3; 103(39):2845-7. PubMed ID: 17128916
[No Abstract] [Full Text] [Related]
12. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
[TBL] [Abstract][Full Text] [Related]
13. Risk of noncardiac surgery in the months following placement of a drug-eluting coronary stent.
Auer J; Berent R; Weber T; Eber B
J Am Coll Cardiol; 2004 Feb; 43(4):713; author reply 714-5. PubMed ID: 14975489
[No Abstract] [Full Text] [Related]
14. Stent thrombosis after percutaneous coronary intervention for bifurcation lesions.
Tan HC
J Interv Cardiol; 2009 Apr; 22(2):114-6. PubMed ID: 19379468
[TBL] [Abstract][Full Text] [Related]
15. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
Kumbhani DJ; Bavry AA; Bhatt DL
Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
[TBL] [Abstract][Full Text] [Related]
16. Very late thrombosis after implantation of sirolimus eluting stent.
Karvouni E; Korovesis S; Katritsis DG
Heart; 2005 Jun; 91(6):e45. PubMed ID: 15894746
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous subacute stent thrombosis after implantation of sirolimus-eluting stent and bare-metal stent.
Kang WC; Moon CI; Ahn TH; Shin EK
Int J Cardiol; 2008 Jul; 127(2):e89-92. PubMed ID: 17689731
[TBL] [Abstract][Full Text] [Related]
18. Late stent thrombosis--the "vulnerable" stent.
Waksman R
Catheter Cardiovasc Interv; 2007 Jul; 70(1):54-6. PubMed ID: 17585385
[No Abstract] [Full Text] [Related]
19. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
